Study guide
4.3 Reference Safety Information and IB Updates
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
4.3 Reference Safety Information and IB Updates
Key Takeaways Explain This Topic AI
Expectedness uses the applicable version-controlled reference safety information.
The IB is reviewed at least annually and revised when needed.
Important new safety information may need communication before a scheduled IB revision.
Last updated: October 2026
Reference Safety Information and IB Updates
The Reference Safety Information (RSI) is the specific section of the Investigator's Brochure (typically located within the designated safety information) that serves as the legal and regulatory benchmark for determining whether a serious adverse reaction is "expected" or "unexpected."
Why the RSI is Vital for Expedited Safety Reporting
Under ICH E2A , expedited safety reporting is reserved for events meeting three concurrent criteria:
Serious: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, causes a congenital anomaly/birth defect, or is an important medical event.
Related (Adverse Reaction): A reasonable possibility exists that the investigational product caused the event.
Unexpected: The nature, severity, or frequency of the reaction is not consistent with the Reference Safety Information in the applicable version-controlled IB.
An event meeting seriousness, suspected relationship and unexpectedness criteria is a SUSAR. Under E2A, fatal/life-threatening unexpected suspected reactions are reported as soon as possible within seven calendar days after qualifying knowledge, with as complete a follow-up as possible within eight additional days. Other serious unexpected suspected reactions are reported as soon as possible within fifteen calendar days after minimum criteria are met. Follow-up information should be actively sought; a complete final hospital record is not a prerequisite to the initial report.
An expected serious reaction ordinarily does not qualify for individual SUSAR reporting, but the investigator still follows SAE reporting requirements and the sponsor evaluates cumulative information. A clinically important increase in an expected reaction rate or another important finding can require rapid communication under E2A. Do not assume that an expected classification makes information unimportant.
Annual review and version control
E6(R3) Appendix A calls for IB review at least annually and revision as necessary under sponsor procedures. Important new information may need communication to investigators, IRBs/IECs or authorities before a revised IB is available. The appropriate action depends on the finding; there is no universal requirement to use one named letter format. Preserve the applicable edition and history so earlier expectedness assessments and site decisions remain interpretable.
The CRA should trace version distribution, appropriate investigator/staff review, relevant ethics handling and any consent or protocol implications. A signed receipt is evidence of receipt, not proof that a new risk was incorporated into site practice. Ask whether affected staff understand what changes and whether the participant information needs timely updating.
Interpreting background safety information
A nonclinical finding can support targeted clinical surveillance without determining one universal schedule. For example, a sponsor may incorporate cardiac assessments when background information suggests a cardiac risk. The actual frequency, thresholds and responses belong in the authorised protocol and associated instructions. A CRA verifies those requirements and confirms investigator review of results; the CRA must not invent stopping rules from an IB summary.
The IB should provide balanced guidance, including limitations and relevant negative findings. Distinguish product-specific observations from a class effect, an anticipated risk from an established adverse reaction, and background scientific information from the designated RSI. A general list of possible risks cannot automatically make every serious reaction expected. Preserve the edition used for each assessment so historical decisions can be reconstructed.
For investigational devices, use the relevant instructions for use (IFU) , product information and protocol. Check the approved model/configuration, intended use, handling precautions, required operator training and product traceability. Device terminology in the ECO does not mean FDA device classification rules are examination references. Clinical staff need the current instructions actually applicable to the device supplied, not a brochure for a different marketed model.
CRA Operational Responsibilities: Site-Level IB Management
When conducting monitoring visits, the CRA acts as the primary quality auditor ensuring that the Investigator Site File (ISF) reflects the current safety reality of the investigational product.
The CRA Monitoring Checklist for IB Updates
Version Reconciliation: Confirm that the active IB version in the ISF matches the master version documented in the Trial Master File (TMF). Confirm that obsolete versions are stamped "SUPERSEDED" and retained in historical files. Prior versions must never be thrown away or destroyed.
Training Documentation: Verify that the Principal Investigator and affected staff received and understood relevant updated information, with documentation appropriate to their roles.
IRB/IEC Compliance: Verify that the updated IB was submitted promptly to the site's IRB/IEC. Check for the evidence of required IRB/IEC submission and handling and ensure it is filed in the regulatory binder.
Informed Consent Form (ICF) Assessment: If the updated IB introduces new safety risks or alters the risk-benefit assessment, verify that the sponsor provided an updated model ICF. Check whether the site updated its local ICF, secured IRB approval, and re-consented all actively enrolled participants who remain exposed to trial interventions.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9 , ICH E9(R1) , ICH E8(R1) .